Novo Nordisk Launches Novo Rebrand and New Corporate Culture
BAGSVAERD, Denmark — September 14, 2026 Novo Nordisk A/S announced the launch of a new corporate brand centred on...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
BAGSVAERD, Denmark — September 14, 2026 Novo Nordisk A/S announced the launch of a new corporate brand centred on...
Ahmedabad, India / Pennington, New Jersey, August 4, 2026 Zydus Lifesciences Limited has received final approval from the U.S....
MUMBAI, India, and NAPLES, Fla., July 28, 2026 Lupin Limited has received U.S. Food and Drug Administration (FDA) approval...
MUMBAI, India & NAPLES, Fla., June 26, 2026 Lupin Limited announced that it has received tentative approval from the...
MUMBAI, India, April 24, 2026 Cipla Limited continues to reinforce its position as a leading global pharmaceutical company, advancing...
SEATTLE, WA – November 13, 2025 — Pelthos Therapeutics released its third-quarter fiscal 2025 financial results, highlighting strong R&D...
Prague, Czech Republic; London, UK; Chicago, US – September 11, 2025 – Zentiva, a leading European generics pharmaceutical company,...
